创新药出海加速，龙头BD大单频出！行情一触即发？

Group 1 - The article highlights the opportunities in the Hong Kong Stock Connect for innovative drugs, particularly focusing on the outbound licensing transactions of Chinese innovative drugs since 2026 [1][4][5] - Significant milestone payments and upfront payments for various transactions are detailed, showcasing the financial potential of these deals [1][4][5] - Notable transactions include: - CSPC Pharmaceutical's deal with AstraZeneca for $17.3 billion with an upfront payment of $1.2 billion - Innovent Biologics' agreement with Eli Lilly for $8.5 billion with an upfront payment of $350 million - Rongchang Biologics' transaction with AbbVie for $4.95 billion with an upfront payment of $650 million [1][4][5] Group 2 - Other transactions listed include: - Zai Lab's deal with AbbVie for $1.135 billion with an upfront payment of $100 million - Haicheng Pharmaceutical's agreement with AirNexis for $955 million with an upfront payment of $108 million - Xiansheng Pharmaceutical's deal with Boehringer Ingelheim for €1.016 billion with an upfront payment of €42 million - Yilian Biologics' agreement with Roche for $570 million with undisclosed upfront payment [1][4][5]